molecules of the month


oral ATM kinase inhibitor

Ph. I candidate oncology

biochem-based screen. and BBB penetration opt

J Pharmacol Exp Ther

AstraZeneca, Cambridge, UK

AZD1390 chemical structure oral ATM kinase inhibitor - AstraZeneca, Cambridge, UK
4 mins read

Context. AZD1390 (recently published on by University of Minnesota) is a brain-penetrating Ataxia-Telangiectasia Mutated (ATM) kinase inhibitor under development for brain tumors. The kinase, known for its critical role in the repair of lethal DNA lesions induced by radiotherapy treatment, is considered an attractive target for CNS tumors because coupling its inhibition with radiotherapy may lead to radiosensitization of tumor cells. In a recent publication, University of Minnesota scientists investigated the CNS penetration of AZD1390 in mice using transporter knockout models lacking efflux transporters P-gp and Bcrp. Although the compound was found to be an active substrate of P-gp which limited its CNS exposure, effective total concentrations for radiosensitization were still achieved. The compound is currently being evaluated in four…

request a trial

You don’t have time to read everything, but you can’t afford to fall behind.

Drug Hunter Premium is drug discovery, distilled, so you can quickly catch up and make informed decisions based on industry examples.

Get ahead now by requesting a trial.

already a member? log in: